This approach has shown functional improvement for mutant forms of BSEP in cell culture and clinical improvements in children with ABCB11 disease (PFIC2).86 These drugs are approved for use in children with select urea cycle defects and therefore may be considered for certain patients and gene variants. The gene discussed is ABCB11; the disease is progressive familial intrahepatic cholestasis type 2.